Bioventus (BVS) Revenue & Revenue Breakdown
Bioventus Revenue Highlights
Latest Revenue (Y)
$512.35M
Latest Revenue (Q)
$138.96M
Main Segment (Y)
Pain Treatments
Main Geography (Y)
UNITED STATES
Bioventus Revenue by Period
Bioventus Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $512.35M | 0.04% |
| 2022-12-31 | $512.12M | 18.85% |
| 2021-12-31 | $430.90M | 34.17% |
| 2020-12-31 | $321.16M | -5.58% |
| 2019-12-31 | $340.14M | 6.57% |
| 2018-12-31 | $319.18M | 25.83% |
| 2015-12-31 | $253.65M | 4.43% |
| 2014-12-31 | $242.89M | 4.53% |
| 2013-12-31 | $232.38M | 258.75% |
| 2000-01-01 | $64.77M | - |
Bioventus generated $512.35M in revenue during NA 2023, up 0.04% compared to the previous quarter, and up 160.52% compared to the same period a year ago.
Bioventus Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-09-28 | $138.96M | -8.10% |
| 2024-06-29 | $151.22M | 16.81% |
| 2024-03-30 | $129.46M | -4.41% |
| 2023-12-31 | $135.42M | 12.11% |
| 2023-09-30 | $120.79M | -11.87% |
| 2023-07-01 | $137.07M | 15.13% |
| 2023-04-01 | $119.06M | -5.38% |
| 2022-12-31 | $125.83M | -2.20% |
| 2022-10-01 | $128.66M | -8.32% |
| 2022-07-02 | $140.33M | 19.64% |
| 2022-04-02 | $117.29M | -10.06% |
| 2021-12-31 | $130.41M | 19.77% |
| 2021-10-02 | $108.89M | -0.84% |
| 2021-07-03 | $109.82M | 34.29% |
| 2021-04-03 | $81.78M | -17.05% |
| 2020-12-31 | $98.59M | 14.76% |
| 2020-09-30 | $85.91M | 48.07% |
| 2020-06-30 | $58.02M | -26.23% |
| 2020-03-31 | $78.64M | -19.38% |
| 2019-12-31 | $97.55M | 18.62% |
| 2019-09-28 | $82.24M | 2.58% |
| 2019-06-29 | $80.17M | - |
| 2019-03-29 | $80.17M | 22.58% |
| 2016-03-31 | $65.40M | 22.56% |
| 2015-03-31 | $53.36M | - |
Bioventus generated $138.96M in revenue during Q3 2024, up -8.10% compared to the previous quarter, and up 101.38% compared to the same period a year ago.
Bioventus Revenue Breakdown
Bioventus Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 21 |
|---|---|
| Surgical Solutions | $87.72M |
| Pain Treatments | $221.61M |
| Restorative Therapies | $121.57M |
Bioventus's latest annual revenue breakdown by segment (product or service), as of Dec 21: Pain Treatments (51.43%), Restorative Therapies (28.21%), and Surgical Solutions (20.36%).
Quarterly Revenue by Product
| Product/Service | Sep 24 | Jun 24 | Mar 24 | Jul 22 | Apr 22 | Dec 21 | Oct 21 | Jul 21 | Apr 21 |
|---|---|---|---|---|---|---|---|---|---|
| U.S. Segment | $122.91M | $134.41M | $114.28M | - | - | - | - | - | - |
| International Segment | $16.05M | $16.81M | $15.18M | - | - | - | - | - | - |
| Pain Treatments | - | - | - | $63.91M | $52.05M | - | - | - | - |
| Restorative Therapies | - | - | - | $39.90M | $34.36M | $36.77M | $30.48M | $32.51M | $21.82M |
| Surgical Solutions | - | - | - | $36.52M | $30.88M | - | - | - | - |
| Pain Treatments And Joint Preservation | - | - | - | - | - | - | $60.63M | $56.70M | $41.53M |
| Bone Graft Substitutes | - | - | - | - | - | - | $17.78M | $20.60M | $18.43M |
Bioventus's latest quarterly revenue breakdown by segment (product or service), as of Sep 24: U.S. Segment (88.45%), and International Segment (11.55%).
Bioventus Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|
| Non-US | $62.48M | $14.95M | $43.34M |
| UNITED STATES | $449.86M | $126.21M | $387.55M |
Bioventus's latest annual revenue breakdown by geography, as of Dec 23: UNITED STATES (87.80%), and Non-US (12.20%).
Quarterly Revenue by Country
| Country | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Jul 23 | Dec 22 | Oct 22 | Jul 22 | Apr 22 | Dec 21 | Oct 21 | Jul 21 | Apr 21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-US | $16.05M | $16.81M | $15.18M | $26.90M | $5.42M | $4.41M | $3.24M | $14.02M | $13.21M | $15.24M | $9.73M | $11.13M | $7.24M |
| UNITED STATES | $122.91M | $134.41M | $114.28M | $208.52M | $33.39M | $34.94M | $31.18M | $126.31M | $104.08M | $115.17M | $99.16M | $98.68M | $74.54M |
Bioventus's latest quarterly revenue breakdown by geography, as of Sep 24: UNITED STATES (88.45%), and Non-US (11.55%).
Bioventus Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| BVS | Bioventus | $512.35M | $138.96M |
| RPID | Rapid Micro Biosystems | $22.52M | $7.60M |
| HSCS | Heart Test Laboratories | $18.60M | - |
| VVOS | Vivos Therapeutics | $13.80M | $3.86M |
| NUWE | Nuwellis | $8.86M | $2.37M |
| NAOV | NanoVibronix | $2.28M | $376.00K |
| TIVC | Tivic Health Systems | $1.18M | $126.00K |
| BJDX | Bluejay Diagnostics | - | - |
| BBLG | Bone Biologics | - | - |